Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Two-part, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Chidamide in Combination With Regorafenib in Patients With Hepatocellular Carcinoma

NCT05770882 is registered in ClinicalTrials.gov with Great Novel Therapeutics Biotech & Medicals Corporation as lead sponsor.

NCT NCT05770882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05770882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Two-part, Non-randomized, Open-label Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Chidamide in Combination With Regorafenib in Patients With Hepatocellular Carcinoma
Lead sponsor
Great Novel Therapeutics Biotech & Medicals Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
April 25, 2023
Completion date
January 17, 2025
Enrollment
7 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)